Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 100
1.
Breast Cancer Res Treat ; 203(3): 477-486, 2024 Feb.
Article En | MEDLINE | ID: mdl-37923963

PURPOSE: In the treatment of breast cancer, neo-adjuvant chemotherapy is often used as systemic treatment followed by tumor excision. In this context, planning the operation with regard to excision margins relies on tumor size measured by MRI. The actual tumor size can be determined through pathologic evaluation. The aim of this study is to investigate the correlation and agreement between pre-operative MRI and postoperative pathological evaluation. METHODS: One hundred and ninety-three breast cancer patients that underwent neo-adjuvant chemotherapy and subsequent breast surgery were retrospectively included between January 2013 and July 2016. Preoperative tumor diameters determined with MRI were compared with postoperative tumor diameters determined by pathological analysis. Spearman correlation and Bland-Altman agreement methods were used. Results were subjected to subgroup analysis based on histological subtype (ER, HER2, ductal, lobular). RESULTS: The correlation between tumor size at MRI and pathology was 0.63 for the whole group, 0.39 for subtype ER + /HER2-, 0.51 for ER + /HER2 + , 0.63 for ER-/HER2 +, and 0.85 for ER-/HER2-. The mean difference and limits of agreement (LoA) between tumor size measured MRI vs. pathological assessment was 4.6 mm (LoA -27.0-36.3 mm, n = 195). Mean differences and LoA for subtype ER + /HER2- was 7.6 mm (LoA -31.3-46.5 mm, n = 100), for ER + /HER2 + 0.9 mm (LoA -8.5-10.2 mm, n = 33), for ER-/HER2+ -1.2 mm (LoA -5.1-7.5 mm, n = 21), and for ER-/HER- -0.4 mm (LoA -8.6-7.7 mm, n = 41). CONCLUSION: HER2 + and ER-/HER2- tumor subtypes showed clear correlation and agreement between preoperative MRI and postoperative pathological assessment of tumor size. This suggests that MRI evaluation could be a suitable predictor to guide the surgical approach. Conversely, correlation and agreement for ER + /HER2- and lobular tumors was poor, evidenced by a difference in tumor size of up to 5 cm. Hence, we demonstrate that histological tumor subtype should be taken into account when planning breast conserving surgery after NAC.


Breast Neoplasms , Humans , Female , Breast Neoplasms/diagnostic imaging , Breast Neoplasms/drug therapy , Breast Neoplasms/surgery , Neoadjuvant Therapy/methods , Retrospective Studies , Receptor, ErbB-2 , Magnetic Resonance Imaging/methods , Antineoplastic Combined Chemotherapy Protocols/therapeutic use
2.
Phys Imaging Radiat Oncol ; 23: 66-73, 2022 Jul.
Article En | MEDLINE | ID: mdl-35814260

Background and purpose: Magnetic resonance (MR)-linac delivery is expected to improve organ at risk (OAR) sparing. In this study, OAR doses were compared for online adaptive MR-linac treatments and conventional cone beam computed tomography (CBCT)-linac radiotherapy, taking into account differences in clinical workflows, especially longer session times for MR-linac delivery. Materials and methods: For 25 patients with pelvic/abdominal lymph node oligometastases, OAR doses were calculated for clinical pre-treatment and daily optimized 1.5 T MR-linac treatment plans (5 × 7 Gy) and compared with simulated CBCT-linac plans for the pre-treatment and online anatomical situation. Bowelbag and duodenum were re-contoured on MR-imaging acquired before, during and after each treatment session. OAR hard constraint violations, D0.5cc and D10cc values were evaluated, focusing on bowelbag and duodenum. Results: Overall, hard constraints for all OAR were violated less often in daily online MR-linac treatment plans compared with CBCT-linac: in 5% versus 22% of fractions, respectively. D0.5cc and D10cc values did not differ significantly. When taking treatment duration and intrafraction motion into account, estimated delivered doses to bowelbag and duodenum were lower with CBCT-linac if identical planning target volume (PTV) margins were used for both modalities. When reduced PTV margins were achievable with MR-linac treatment, bowelbag doses were lower compared with CBCT-linac. Conclusions: Compared with CBCT-linac treatments, the online adaptive MR-linac approach resulted in fewer hard planning constraint violations compared with single-plan CBCT-linac delivery. With respect to other bowelbag/duodenum dose-volume parameters, the longer duration of MR-linac treatment sessions negatively impacts the potential dosimetric benefit of daily adaptive treatment planning.

3.
Osteoporos Int ; 29(12): 2677-2683, 2018 Dec.
Article En | MEDLINE | ID: mdl-30167720

BMD changes in patients under tight control (monitored at 3-month intervals with adjustment of therapy guided by bone turnover markers) and routine management (controlled once a year) were compared. After 1 year, the femoral neck BMD increased significantly in the tight control compared to the routine management group. INTRODUCTION: We intended to ascertain whether tight control (i.e., follow-up visits and bone turnover markers/BTM/and parathyroid hormone/PTH/monitoring at 3-month intervals) strategy achieves a statistically greater increase in bone mineral density over the observation period than standard follow-up care (i.e., bone densitometry at 1-year intervals, without BTM monitoring). METHODS: We studied involutional osteoporotic patients newly enrolled into chronic care. One hundred and eleven patients underwent tight control, while another 113 received routine treatment (with follow-up visits scheduled at > 1-year intervals). We compared the changes in bone mineral density reflected by the results of bone mineral density (BMD) measurements of the lumbar spine and of the left femoral neck. Statistical analyses were performed with version 22 of the SPSS software package. RESULTS: In the group of patients under tight control, baseline and follow-up median BMD values were 0.842/0.881 g/cm2 at the L1-4 vertebrae and 0.745/0.749 g/cm2 at the femoral neck. In the group under routine care, the corresponding values were 0.903/0.915 g/cm2 and 0.742/0.72 g/cm2, respectively. The relative changes of the bone mineral density of the femoral neck was significantly (p = 0.041) higher in patients under tight control than in those receiving routine care; however, BMD changes in the lumbar spine were not statistically different. CONCLUSION: Our findings suggest that adopting tight control as a new therapeutic strategy might be justified in the osteoporosis management. In fact, a greater improvement of BMD can be achieved by treatment according to these principles.


Bone Density Conservation Agents/therapeutic use , Drug Monitoring/methods , Osteoporosis/drug therapy , Absorptiometry, Photon , Adult , Aged , Aged, 80 and over , Biomarkers/blood , Bone Density/drug effects , Bone Density/physiology , Bone Remodeling/physiology , Female , Femur Neck/physiopathology , Follow-Up Studies , Humans , Long-Term Care/methods , Lumbar Vertebrae/physiopathology , Male , Middle Aged , Osteoporosis/physiopathology
4.
5.
Eur J Surg Oncol ; 43(10): 1846-1854, 2017 Oct.
Article En | MEDLINE | ID: mdl-28688723

BACKGROUND: Re-excision after breast conserving surgery (BCS) for invasive breast cancer (IBC) can be omitted for focally positive margins in the Netherlands, but this guideline is not routinely followed. Focally positive and extensively positive margins have rarely been studied separately and compared to negative margins regarding clinicopathological predictors, residual disease incidence, and local recurrence. METHODS: All females with BCS for Tis-T3, without neo-adjuvant chemotherapy between 2005 and 2014 at one university hospital were included. Clinicopathological and follow-up information was collected from electronic patient records. Index tumor samples from all patients with re-excision were reviewed by one pathologist. Margins were classified as negative (≥2 mm width), close (<2 mm width), focally positive (≤4 mm length of tumor touching inked margin), or extensively positive (>4 mm length). RESULTS: From 499 patients included, 212 (43%) had negative, 161 (32%) had close, 59 (12%) had focally positive, and 67 (13%) had extensively positive margins. Increasingly involved margins were associated with lobular type, tumor size, and adjacent DCIS in IBC patients and lesion size in purely DCIS patients. In IBC patients, 17%, 49%, and 77% had re-excision after close, focally positive, and extensively positive margins and residual disease incidence was 55%, 50%, and 70% respectively. In purely DCIS patients, 26 (65%), 13 (87%), and 16 (94%) had re-excision after close, focally positive, and extensively positive margins and residual disease incidence was 39%, 46%, and 90% respectively. CONCLUSION: Incidence of residual disease after focally positive margins was not different from close margins, but was significantly higher after extensively positive margins. We recommend quantifying extent of margin involvement in all pathology reports.


Breast Neoplasms/surgery , Mastectomy, Segmental/methods , Neoplasm Recurrence, Local/epidemiology , Neoplasm Staging , Breast Neoplasms/diagnosis , Breast Neoplasms/epidemiology , Female , Follow-Up Studies , Humans , Incidence , Middle Aged , Neoplasm Recurrence, Local/surgery , Neoplasm, Residual , Netherlands/epidemiology , Prognosis , Reoperation , Retrospective Studies
6.
J Eur Acad Dermatol Venereol ; 30(9): 1531-6, 2016 Sep.
Article En | MEDLINE | ID: mdl-27393182

BACKGROUND: There are conflicting data on the occurrence of subclinical myocardial dysfunction in psoriatic patients and on the impact of long-term tumour necrosis factor-alpha (TNF-α) inhibitor therapy on cardiac function. OBJECTIVE: In this study, we explored whether there are any signs of subclinical cardiovascular disease (echocardiographic abnormalities) in severe psoriatic patients without clinically overt heart disease. As a second objective, the influence of long-term treatment with TNF-α inhibitors on the ventricular functions of psoriatic patients was also investigated. METHODS: Clinical and echocardiographic data from 44 psoriatic patients and 45 age- and sex-matched controls were processed. As a first step, the echocardiographic parameters of psoriatic patients obtained before anti-TNF-α treatment were compared with controls. As a second step, to detect the effect of long-term anti-TNF-α treatment on echocardiographic parameters, data of patients before and after therapy were analysed. RESULTS: The right ventricular Tei index was higher (P < 0.001), whereas the tricuspid annular plane systolic excursion (TAPSE) and right ventricular free wall peak systolic velocity were lower (P < 0.001 and P < 0.0001, respectively) in the psoriatic patients than in the controls. Following treatment with TNF-α inhibitors, TAPSE and right ventricular free wall peak systolic velocity significantly improved (P < 0.0001 for both parameters). The Tei index of both ventricles improved during biological therapy; however, this change did not reach statistical significance. CONCLUSION: Patients with severe psoriasis exhibit signs of subclinical cardiovascular disease compared to control, and prolonged anti-TNF-α therapy has a potentially beneficial effect on these signs.


Cardiovascular Diseases/complications , Dermatologic Agents/therapeutic use , Psoriasis/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adult , Cardiovascular Diseases/diagnostic imaging , Echocardiography , Female , Humans , Male , Middle Aged , Psoriasis/complications
7.
Synapse ; 69(6): 295-8, 2015 Jun.
Article En | MEDLINE | ID: mdl-25764479

The authors show that the dopamine D3 antagonist SB-277011-A consistently and persistently decrease binge-like EtOH consumption at 30 mg/kg and it decreases binge-like consumption on days 3, 7, 9, and 11-13 at 15 mg/kg. These findings suggest that the brain's D3 receptor may also be involved in not only ethanol reward but binge drinking as well.


Alcohol Deterrents/pharmacology , Binge Drinking/drug therapy , Nitriles/pharmacology , Receptors, Dopamine D3/antagonists & inhibitors , Tetrahydroisoquinolines/pharmacology , Animals , Binge Drinking/metabolism , Central Nervous System Depressants/administration & dosage , Dopamine Antagonists/pharmacology , Drinking/drug effects , Drinking Water/administration & dosage , Ethanol/administration & dosage , Mice, Inbred C57BL , Random Allocation , Receptors, Dopamine D3/metabolism
8.
Eur J Cancer ; 49(16): 3462-70, 2013 Nov.
Article En | MEDLINE | ID: mdl-23867124

BACKGROUND: Rhabdomyosarcoma (RMS) is an aggressive soft tissue tumour mainly affecting children and adolescents. Since survival of high-risk patients remains poor, new treatment options are awaited. The aim of this study is to investigate anaplastic lymphoma kinase (ALK) and insulin-like growth factor-1 receptor (IGF-1R) as potential therapeutic targets in RMS. PATIENTS AND METHODS: One-hundred-and-twelve primary tumours (embryonal RMS (eRMS)86; alveolar RMS (aRMS)26) were collected. Expression of IGF-1R, ALK and downstream pathway proteins was evaluated by immunohistochemistry. The effect of ALK inhibitor NVP-TAE684 (Novartis), IGF-1R antibody R1507 (Roche) and combined treatment was investigated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays in cell lines (aRMS Rh30, Rh41; eRMS Rh18, RD). RESULTS: IGF-1R and ALK expression was observed in 72% and 92% of aRMS and 61% and 39% of eRMS, respectively. Co-expression was observed in 68% of aRMS and 32% of eRMS. Nuclear IGF-1R expression was an adverse prognostic factor in eRMS (5-year survival 46.9 ± 18.7% versus 84.4 ± 5.9%, p=0.006). In vitro, R1507 showed diminished viability predominantly in Rh41. NVP-TAE684 showed diminished viability in Rh41 and Rh30, and to a lesser extent in Rh18 and RD. Simultaneous treatment revealed synergistic activity against Rh41 and Rh30. CONCLUSION: Co-expression of IGF-1R and ALK is detected in eRMS and particularly in aRMS. As combined inhibition reveals synergistic cytotoxic effects, this combination seems promising and needs further investigation.


Antineoplastic Combined Chemotherapy Protocols/pharmacology , Molecular Targeted Therapy , Receptor Protein-Tyrosine Kinases/antagonists & inhibitors , Receptor, IGF Type 1/antagonists & inhibitors , Rhabdomyosarcoma, Alveolar/drug therapy , Rhabdomyosarcoma, Embryonal/drug therapy , Adolescent , Adult , Aged , Anaplastic Lymphoma Kinase , Cell Line, Tumor , Cell Survival/drug effects , Chi-Square Distribution , Child , Child, Preschool , Dose-Response Relationship, Drug , Drug Synergism , Humans , Infant , Infant, Newborn , Kaplan-Meier Estimate , Middle Aged , Netherlands , Protein Kinase Inhibitors/pharmacology , Receptor Protein-Tyrosine Kinases/metabolism , Receptor, IGF Type 1/metabolism , Rhabdomyosarcoma, Alveolar/enzymology , Rhabdomyosarcoma, Alveolar/mortality , Rhabdomyosarcoma, Alveolar/pathology , Rhabdomyosarcoma, Embryonal/enzymology , Rhabdomyosarcoma, Embryonal/mortality , Rhabdomyosarcoma, Embryonal/pathology , Young Adult
9.
Crit Rev Oncol Hematol ; 82(3): 259-79, 2012 Jun.
Article En | MEDLINE | ID: mdl-21802959

Rhabdomyosarcoma (RMS) is a rare type of soft tissue sarcoma that mainly affects children, but also occurs in adolescents and (young) adults (AYA). Despite dramatic survival improvements reported by international study groups in children over the past decades, the awareness of a dismal outcome for older patients with RMS has grown. In contrast to the world-wide organization of care for children with RMS, standard care in adults lags behind. A step forward in RMS management for patients of all ages is urgently needed. Both paediatric oncologists and medical oncologists are essential players in development of a concept of RMS care, but bringing two worlds together seems not so easy. This review provides an overview which highlights the similarities and differences in children and adults with RMS. Furthermore, it comes up with a novel concept to overcome the virtual gap between the treatment approach of children and AYA with RMS.


Antineoplastic Agents/administration & dosage , Rhabdomyosarcoma/therapy , Soft Tissue Neoplasms/therapy , Adolescent , Age Factors , Antineoplastic Agents/therapeutic use , Cell Transformation, Neoplastic/genetics , Child , Child, Preschool , Clinical Trials as Topic , Female , Genetic Predisposition to Disease , Humans , Infant , Male , Neoplasm Staging , Rhabdomyosarcoma/genetics , Rhabdomyosarcoma/mortality , Rhabdomyosarcoma/surgery , Soft Tissue Neoplasms/genetics , Soft Tissue Neoplasms/mortality , Soft Tissue Neoplasms/surgery , Survival Rate , Young Adult
10.
J Clin Oncol ; 30(3): 308-15, 2012 Jan 20.
Article En | MEDLINE | ID: mdl-22184391

PURPOSE: The aim of this study is to investigate anaplastic lymphoma kinase (ALK) protein expression and underlying genetic aberrations in rhabdomyosarcoma (RMS), with special attention to clinical and prognostic implications. PATIENTS AND METHODS: A total of 189 paraffin-embedded RMS tumor specimens from 145 patients were collected on tissue microarray. ALK protein expression was evaluated by immunohistochemistry. ALK gene (2p23) copy number and translocations were determined by in situ hybridization. cDNA sequencing of the receptor tyrosine kinase domain of the ALK gene was assessed in 43 samples. RESULTS: Strong cytoplasmic ALK protein expression was more frequently observed in alveolar RMS (ARMS) than in embryonal RMS (ERMS) (81% v 32%, respectively; P < .001). ALK gene copy number gain was detected in the vast majority of ARMS (88%), compared with 52% of ERMS (P < .001). ALK copy number correlated with protein expression in primary tumors (n = 107). We identified one point mutation (2%) and seven tumors harboring whole exon deletions (16%). In ERMS, specific ALK gain in the primary tumor correlated with metastatic disease (100% in metastatic disease v 29% in nonmetastatic disease; P = .004) and poor disease-specific survival (5-year disease-specific survival: 62% v 82% for nonspecific or no gain; P = .046). CONCLUSION: Because ALK aberrations on genomic and protein levels are frequently found in RMSs, in particular ARMS, and are associated with disease progression and outcome in ERMS, ALK may play a role in tumor biology and may provide a potential therapeutic target for these tumors. Future research should aim at the oncogenic role of ALK and the potential effect of ALK inhibitors in RMS.


Biomarkers, Tumor/genetics , Receptor Protein-Tyrosine Kinases/genetics , Rhabdomyosarcoma/enzymology , Rhabdomyosarcoma/genetics , Adolescent , Adult , Aged , Anaplastic Lymphoma Kinase , Child , Child, Preschool , Female , Humans , Immunohistochemistry , Infant , Infant, Newborn , Male , Middle Aged , Prognosis , Receptor Protein-Tyrosine Kinases/biosynthesis , Rhabdomyosarcoma/pathology , Translocation, Genetic , Young Adult
11.
Ned Tijdschr Geneeskd ; 154: A2420, 2010.
Article Nl | MEDLINE | ID: mdl-21176267

A 6-month-old male infant with an unremarkable past medical history was admitted to the emergency department in an epileptic state. The seizures were resistant to treatment with conventional drugs. The child was sedated, intubated and admitted to the intensive care department. Despite extensive investigations no underlying disease was found. The seizures persisted and the child was repeatedly admitted to the hospital. Four months after the first presentation, ventricular fibrillation occurred from which the child was successfully resuscitated. His stomach appeared to contain a disinfectant and a severe ethanol-intoxication was found, leading to the diagnosis "Munchausen syndrome by proxy". The incidence of this syndrome is underestimated. Recognition of this potentially fatal phenomenon is often difficult, resulting in a delay in diagnosis. Paediatricians and general practitioners should be aware of this syndrome in children presenting with an unusual disease or an unusual medical history reported by the parents or care providers.


Child Abuse/diagnosis , Disinfectants/toxicity , Epilepsy/chemically induced , Munchausen Syndrome by Proxy/diagnosis , Delayed Diagnosis , Diagnosis, Differential , Disinfectants/administration & dosage , Epilepsy/diagnosis , Ethanol/administration & dosage , Ethanol/toxicity , Humans , Infant , Male , Methanol/administration & dosage , Methanol/toxicity
12.
Scand J Rheumatol ; 39(6): 490-7, 2010 Nov.
Article En | MEDLINE | ID: mdl-20615161

OBJECTIVE: The aim of this study was to perform a quantitative and functional analysis of natural CD4+CD25(high)Foxp3+ regulatory T cells (nTregs) and CD4+IL-17+ T cells, and to assess the serum levels of proinflammatory cytokines in patients with undifferentiated connective tissue disease (UCTD) before and after 5 weeks of 0.5 µg/day alfacalcidol supplementation. METHODS: Twenty-five patients with UCTD were enrolled in an open-label trial of alfacalcidol. Plasma levels of 25-hydroxyvitamin D [25(OH)D] were assessed by a high-performance liquid chromatography (HPLC) method. Flow cytometry was used for the quantification of nTregs and the IL-17 expression of T-helper (Th)17 cells. The serum concentrations of cytokines interleukin (IL)-12, interferon (IFN)-γ, IL-23, IL-17, IL-6, and IL-10 were measured by an enzyme-linked immunosorbent assay (ELISA). RESULTS: Treatment with alfacalcidol raised 25(OH)D levels from a mean of 23.5 ± 5.6 to 34.5 ± 7.4 ng/mL (p = 0.059; NS). Alfacalcidol treatment decreased both Th1- (IL-12 and IFN-γ) and Th17-related (IL-23, IL-17, IL-6) cytokine levels in UCTD patients, while the soluble IL-10 level increased (IL-12: 156.7 ± 75.2 vs. 87.5 ± 42.1 pg/mL, p < 0.001; IFN-γ: 41.5 ± 12.0 vs. 21.7 ± 9.9 pg/mL, p < 0.001; IL-23: 385.2 ± 82.2 vs. 210.0 ± 69.3 pg/mL, p < 0.001; IL-17: 37.8 ± 9.6 vs. 17.8 ± 4.5 pg/mL, p = 0.009; IL-6: 39.4 ± 11.3 vs. 23.5 ± 6.3 pg/mL, p < 0.001, IL-10: 8.4 ± 3.0 vs. 21.4 ± 9.7 pg/mL, p < 0.001). Alfacalcidol improved the Th17/nTreg imbalance, as it inhibited the IL-17 expression of Th17 cells, and increased the number of nTregs. The alfacalcidol might increase the capacity of nTreg cells to suppress the proliferation of autologous CD4+CD25⁻ cells. CONCLUSION: Our findings support the idea that vitamin D influences the Th17/nTreg imbalance in vitamin D-insufficient patients with UCTD and could be beneficial in the management of the disease.


Bone Density Conservation Agents/adverse effects , Connective Tissue Diseases/immunology , Homeostasis/drug effects , Hydroxycholecalciferols/adverse effects , T-Lymphocytes, Regulatory/drug effects , Th17 Cells/drug effects , Vitamin D Deficiency/immunology , Adult , Autoantibodies/blood , Bone Density Conservation Agents/therapeutic use , Cytokines/blood , Cytokines/metabolism , Female , Forkhead Transcription Factors/blood , Forkhead Transcription Factors/metabolism , Homeostasis/immunology , Humans , Hydroxycholecalciferols/therapeutic use , Interleukin-17/blood , Interleukin-17/metabolism , Middle Aged , T-Lymphocytes, Regulatory/immunology , Th17 Cells/immunology , Vitamin D/blood , Vitamin D/metabolism , Vitamin D Deficiency/drug therapy , Young Adult
13.
Ann Oncol ; 20(2): 365-73, 2009 Feb.
Article En | MEDLINE | ID: mdl-18725392

BACKGROUND: Lack of survival improvement in adolescents and young adults (AYA) with cancer has led to increased awareness of this young population. DESIGN: We carried out a population-based study of incidence and survival of primary tumours and second primary tumours in patients aged 12-24 in north Netherlands. Age-specific incidence rates per 100,000 and 3-year moving means were calculated. Factors associated with incidence and survival were assessed using a Poisson model, log-rank test and multivariate Cox proportional hazards analysis. RESULTS: From 1989 to 2003 a total of 1118 patients were diagnosed. The total age-specific incidence rates per 100,000 were as follows: males: 13.4 (12-15 years), 26.9 (16-19 years) and 27.5 (20-24 years) and females: 13.9, 20.7 and 20.7. Male : female ratio was 1.32. The overall estimated annual percentage change (EAPC) in incidence was 2.15% (P < 0.01). Five-year survival was 80.8% and did not improve during the study period. With median follow-up of 5.5 years (range 0.0-16.0) in our cohort the standardized incidence ratio (SIR) of second primary tumours was 30.55 (95% confidence interval = 19.96-44.76, P < 0.05). CONCLUSIONS: The total incidence of cancer in AYA increased (EAPC = 2.15%). Survival was unchanged. The SIR of a second primary tumour in this young cohort increased 31-fold. Further research is needed to study this increasing incidence and optimise treatment outcome in these young patients.


Neoplasms, Second Primary/epidemiology , Neoplasms/epidemiology , Adolescent , Child , Cohort Studies , Confidence Intervals , Female , Follow-Up Studies , Geography , Humans , Incidence , Male , Neoplasms/mortality , Neoplasms, Second Primary/etiology , Netherlands/epidemiology , Population Surveillance , Proportional Hazards Models , Retrospective Studies , Survival Analysis , Time Factors , Young Adult
14.
Scand J Immunol ; 68(3): 261-9, 2008 Sep.
Article En | MEDLINE | ID: mdl-18510590

Vitamin D, besides having well-known control functions of calcium and phosphorus metabolism, bone formation and mineralization, also has a role in the maintenance of immune-homeostasis. The immune-regulatory role of vitamin D affects both the innate and adaptive immune system contributing to the immune-tolerance of self-structures. Impaired vitamin D supply/regulation, amongst other factors, leads to the development of autoimmune processes in animal models of various autoimmune diseases. The administration of vitamin D in these animals leads to improvement of immune-mediated symptoms. Moreover, in human autoimmune diseases, such as multiple sclerosis, or rheumatoid arthritis the pathogenic role of vitamin D has been described. The review aims at describing the complex immune-regulatory role of vitamin D from the cellular level through autoimmune animal models and depicting the known contribution of vitamin D in the pathogenesis of human autoimmune diseases.


Autoimmune Diseases/physiopathology , Vitamin D Deficiency/immunology , Vitamin D/physiology , Animals , Autoimmune Diseases/blood , Autoimmune Diseases/diet therapy , Disease Models, Animal , Humans , Immunity, Active , Immunity, Innate , Mice , Receptors, Calcitriol/metabolism , Vitamin D/blood , Vitamin D/pharmacology , Vitamin D/therapeutic use
15.
Genet Couns ; 14(4): 407-11, 2003.
Article En | MEDLINE | ID: mdl-14738114

Proximal duplications of the long arm of chromosome 1 are rare and the few patients that have been described in literature have multiple congenital abnormalities and/or mental retardation. The present paper describes the clinical and cytogenetic findings of an adult patient with only mild mental retardation and some minor malformations. The patient carries an inverted duplication of 1q12q21.2.


Chromosomes, Human, Pair 1 , Gene Duplication , Intellectual Disability/genetics , Adult , Humans , Male
16.
Clin Genet ; 62(4): 315-20, 2002 Oct.
Article En | MEDLINE | ID: mdl-12372060

The characteristic clinical features of the dup(3q) syndrome include typical facial features, mental and growth retardation, and (often) congenital heart anomalies. However, pure duplication of 3qter is rare because most of the reported cases are patients who carry an unbalanced translocation and, in addition to the duplication for 3qter, have a deletion for another chromosomal segment. A new case with a pure duplication of 3q detected in a 2-month-old boy is presented here. Extensive cytogenetic analysis revealed an inverted duplication of the distal part of 3q (chromosomal band 3q26.3 up to the telomere), with no (detectable) loss of the original telomeric sequences. Clinical evaluation revealed several phenotypic hallmarks characteristic for the dup(3q) syndrome. By comparing the duplicated region of this patient with the duplicated regions of the other patients with a pure duplication of 3q, we were able to localize the critical region for the dup(3q) phenotype to band 3q26.3. Alongside this new case with a pure duplication of 3q, an overview of six previous cases is given.


Chromosome Aberrations , Chromosome Disorders , Chromosomes, Human, Pair 3 , Heart Defects, Congenital/genetics , Intellectual Disability/genetics , Face/abnormalities , Heart Defects, Congenital/complications , Humans , In Situ Hybridization, Fluorescence , Infant , Intellectual Disability/complications , Karyotyping , Male , Phenotype
18.
Nucl Med Commun ; 23(1): 39-46, 2002 Jan.
Article En | MEDLINE | ID: mdl-11748436

The aim of this study was to test the applicability of 99mTc-hexamethylpropylene amine oxime (99mTc-HMPAO) labelled leukocyte joint scintigraphy in the assessment of disease activity in 21 patients with rheumatoid arthritis, and to compare leukocyte scintigraphy with the Disease Activity Score (DAS), a validated activity index developed by the European League Against Rheumatism (EULAR). Twenty-one patients with rheumatoid arthritis were investigated by using 99mTc-HMPAO labelled leukocyte joint scintigraphy. The clinical and laboratory data were recorded, and the DAS was calculated and compared with the scintigraphic results in each case. A relatively high DAS score (4.71+/-1.07) was found in the majority of patients. The degree of accumulation of 99mTc-HMPAO leukocytes showed no correlation with a patient's age, gender, duration of disease, use of disease modifying anti-rheumatic drugs (DMARDs), visual analogue scale (VAS), Richie index, DAS, or any laboratory parameters. In contrast, a significant correlation was found between the global regional accumulation of the labelled leukocytes of the hands and feet, and the swollen-joint count. It is concluded that radiolabelled leukocyte scintigraphy could become one of the promising methods in the assessment of disease activity in patients with rheumatoid arthritis.


Arthritis, Rheumatoid/diagnostic imaging , Radiopharmaceuticals , Technetium Tc 99m Exametazime , Adult , Arthritis, Rheumatoid/pathology , Female , Foot/diagnostic imaging , Hand/diagnostic imaging , Humans , Leukocytes/diagnostic imaging , Male , Middle Aged , Radionuclide Imaging
19.
Neurobiology (Bp) ; 8(2): 143-66, 2000.
Article En | MEDLINE | ID: mdl-11061212

The efficacy of many drugs relies on their presence at the site of action over a period of time. The retardation or programmed release capability of the conventional dosage forms like oral and parenteral are limited and toxic and undesired side-effects may occur after their applications. These problems may be solved using transdermal delivery systems. Transdermal systems are aimed for local, or systemic action. In the letter case controlling the rate of delivery or modulating the distribution in the organism. The selection of an adequate biological method of evaluating a new transdermal formulation is a critical point of the development. The in vitro methods can help in the characterization of the different formulas, but without an in vivo disposition study they cannot give relevant information about the expectable therapeutic behavior. We adapted and improved an in vivo test system for the evaluation of new transdermal particulate systems (patches) and liposomes containing deprenyl selegiline as active ingredient. The in vivo evaluation system consists of two steps: 1. Full biodisposition study on guinea pig, using isotope labeled selegiline. 2. Biodisposition studies on domestic pigs including dose, area, surface dependence and comparative bioavailability with traditional dosage forms and application moods. Specific examples of these studies and experimental technology are presented.


Chemistry, Pharmaceutical/methods , Monoamine Oxidase Inhibitors/pharmacokinetics , Selegiline/pharmacokinetics , Administration, Cutaneous , Animals , Guinea Pigs , Liposomes , Models, Animal , Swine , Tissue Distribution , Tritium/pharmacokinetics
20.
Appl Occup Environ Hyg ; 15(10): 794-802, 2000 Oct.
Article En | MEDLINE | ID: mdl-11036730

Administrative data sources were used to describe the work-related injuries of drywall carpenters, to calculate rates of occurrence, and to explore high risk sub-groups. Health insurance eligibility files were used to identify a cohort of active union carpenters affiliated with a union local whose predominant work involved drywall installation in the state of Washington. These files contained the hours worked by each individual for each month between January 1989 and December 1995, providing person-hours at risk as a union carpenter. The Washington Department of Labor and Industries (L&I) provided records of workers' compensation claims filed by these individuals. Over seven years 1773 drywall carpenters filed 2567 workers' compensation claims representing an overall rate of 53.3 per 200,000 hours worked. These claims were filed by 1046 different individuals, or 59.0 percent of the cohort. Claims resulting in paid lost time from work were filed at a rate of 12.5 per 200,000 hours worked (n = 609) by 445 (25.1%) different individuals. The most common mechanisms of injury involved being struck (38.3%), overexertion (28.1%), and falls (13.2%). Struck by injuries most commonly involved cuts to the upper extremity. Overexertion injuries were most commonly described as sprains or strains involving the back. Sheetrock was associated with over 40 percent of these injuries. Falls most commonly involved injuries to the knee followed by the back and multiple injuries. Struck by injuries decreased steadily with increasing age and increasing time in the union. There was a steady increase in the rate of falls with increasing age. Overexertion injuries were responsible for the greatest proportion of costs for medical care, permanent impairment, and paid lost days. The high rates of overexertion injuries among these workers is consistent with known ergonomic stresses on drywall jobs. However, these workers are also at high risk of acute traumatic injuries.


Occupational Diseases/epidemiology , Wounds and Injuries/epidemiology , Adolescent , Adult , Aged , Cohort Studies , Cost of Illness , Humans , Middle Aged , Occupational Diseases/economics , Occupational Diseases/prevention & control , Regression Analysis , Washington/epidemiology , Workers' Compensation/statistics & numerical data
...